NCT00831844 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 10
- group Id
- BG004
- value
- 14
- group Id
- BG005
- value
- 20
- group Id
- BG006
- value
- 10
- group Id
- BG007
- value
- 10
- group Id
- BG008
- value
- 9
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 116
- units
- Participants
- groups
- description
- Group 1 - Recurrent or Refractory Hepatoblastoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. cixutumumab: Given IV laboratory biomarker analysis: Correlative studies
- id
- BG000
- title
- Group 1 - Recurrent or Refractory Hepatoblastoma
- description
- Group 2 - Recurrent or Refractory Synovial Sarcoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. cixutumumab: Given IV laboratory biomarker analysis: Correlative studies
- id
- BG001
- title
- Group 2 - Recurrent or Refractory Synovial Sarcoma
- description
- Group 3 - Recurrent or Refractory Rhabdomyosarcoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. cixutumumab: Given IV laboratory biomarker analysis: Correlative studies
- id
- BG002
- title
- Group 3 - Recurrent or Refractory Rhabdomyosarcoma
- description
- Group 4 - Recurrent or Refractory Adrenocortical Carcinoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. cixutumumab: Given IV laboratory biomarker analysis: Correlative studies
- id
- BG003
- title
- Grp 4-Recurrent or Refractory Adrenocortical Carcinoma
- description
- Group 5 - Recurrent or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. cixutumumab: Given IV laboratory biomarker analysis: Correlative studies
- id
- BG004
- title
- Grp 5-Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- description
- Group 6 - Recurrent or Refractory Neuroblastoma -MIBG Positive Without Measurable Disease. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. cixutumumab: Given IV laboratory biomarker analysis: Correlative studies
- id
- BG005
- title
- Grp 6 - Neuroblastoma-MIBG Positive Without Measurable Disease
- description
- Group 7 - Recurrent or Refractory Neuroblastoma -With Measurable Disease. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. cixutumumab: Given IV laboratory biomarker analysis: Correlative studies
- id
- BG006
- title
- Grp 7-Neuroblastoma With Measurable Disease
- description
- Group 8 - Recurrent Osteosarcoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. cixutumumab: Given IV laboratory biomarker analysis: Correlative studies
- id
- BG007
- title
- Group 8 - Recurrent Osteosarcoma
- description
- Group 9 - Recurrent or Refractory Wilms Tumor. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. cixutumumab: Given IV laboratory biomarker analysis: Correlative studies
- id
- BG008
- title
- Group 9 - Recurrent or Refractory Wilms Tumor
- description
- Group 10 - Recurrent or Refractory Retinoblastoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. cixutumumab: Given IV laboratory biomarker analysis: Correlative studies
- id
- BG009
- title
- Group 10 - Recurrent or Refractory Retinoblastoma
- description
- Total of all reporting groups
- id
- BG010
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 16
- group Id
- BG003
- value
- 8
- group Id
- BG004
- value
- 9
- group Id
- BG005
- value
- 18
- group Id
- BG006
- value
- 7
- group Id
- BG007
- value
- 8
- group Id
- BG008
- value
- 9
- group Id
- BG010
- value
- 93
- title
- <=18 years
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 5
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 0
- group Id
- BG010
- value
- 23
- title
- Between 18 and 65 years
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG010
- value
- 0
- title
- >=65 years
- param Type
- NUMBER
- title
- Age, Categorical
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 2
- upper Limit
- 7
- value
- 3
- group Id
- BG001
- lower Limit
- 12
- upper Limit
- 26
- value
- 17.5
- group Id
- BG002
- lower Limit
- 3
- upper Limit
- 22
- value
- 14
- group Id
- BG003
- lower Limit
- 10
- upper Limit
- 29
- value
- 14
- group Id
- BG004
- lower Limit
- 8
- upper Limit
- 28
- value
- 17
- group Id
- BG005
- lower Limit
- 2
- upper Limit
- 30
- value
- 10.5
- group Id
- BG006
- lower Limit
- 4
- upper Limit
- 26
- value
- 14.5
- group Id
- BG007
- lower Limit
- 3
- upper Limit
- 24
- value
- 14.5
- group Id
- BG008
- lower Limit
- 4
- upper Limit
- 14
- value
- 7
- group Id
- BG010
- lower Limit
- 2
- upper Limit
- 30
- value
- 13
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 6
- group Id
- BG004
- value
- 6
- group Id
- BG005
- value
- 8
- group Id
- BG006
- value
- 9
- group Id
- BG007
- value
- 3
- group Id
- BG008
- value
- 8
- group Id
- BG010
- value
- 55
- title
- Female
- categories
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 15
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 8
- group Id
- BG005
- value
- 12
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 7
- group Id
- BG008
- value
- 1
- group Id
- BG010
- value
- 61
- title
- Male
- param Type
- NUMBER
- title
- Gender
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 1
- group Id
- BG008
- value
- 1
- group Id
- BG010
- value
- 15
- title
- Hispanic or Latino
- categories
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 17
- group Id
- BG003
- value
- 8
- group Id
- BG004
- value
- 14
- group Id
- BG005
- value
- 18
- group Id
- BG006
- value
- 8
- group Id
- BG007
- value
- 9
- group Id
- BG008
- value
- 7
- group Id
- BG010
- value
- 96
- title
- Not Hispanic or Latino
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 1
- group Id
- BG010
- value
- 5
- title
- Unknown or Not Reported
- param Type
- NUMBER
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG010
- value
- 0
- title
- American Indian or Alaska Native
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG010
- value
- 5
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG010
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 3
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 3
- group Id
- BG008
- value
- 2
- group Id
- BG010
- value
- 15
- title
- Black or African American
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 13
- group Id
- BG003
- value
- 8
- group Id
- BG004
- value
- 12
- group Id
- BG005
- value
- 16
- group Id
- BG006
- value
- 6
- group Id
- BG007
- value
- 6
- group Id
- BG008
- value
- 6
- group Id
- BG010
- value
- 80
- title
- White
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG010
- value
- 0
- title
- More than one race
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 1
- group Id
- BG008
- value
- 1
- group Id
- BG010
- value
- 16
- title
- Unknown or Not Reported
- param Type
- NUMBER
- title
- Race (NIH/OMB)
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 18
- group Id
- BG003
- value
- 9
- group Id
- BG004
- value
- 14
- group Id
- BG005
- value
- 19
- group Id
- BG006
- value
- 9
- group Id
- BG007
- value
- 10
- group Id
- BG008
- value
- 8
- group Id
- BG010
- value
- 108
- title
- United States
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG010
- value
- 2
- title
- Canada
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 1
- group Id
- BG010
- value
- 6
- title
- Australia
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
- population Description
- Group 10, Recurrent or Refractory Retinoblastoma no patients were enrolled.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 10
- group Id
- BG004
- value
- 14
- group Id
- BG005
- value
- 20
- group Id
- BG006
- value
- 10
- group Id
- BG007
- value
- 10
- group Id
- BG008
- value
- 9
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 116
- units
- Participants
- groups
- description
- Group 1 - Recurrent or Refractory Hepatoblastoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. cixutumumab: Given IV laboratory biomarker analysis: Correlative studies
- id
- BG000
- title
- Group 1 - Recurrent or Refractory Hepatoblastoma
- description
- Group 2 - Recurrent or Refractory Synovial Sarcoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. cixutumumab: Given IV laboratory biomarker analysis: Correlative studies
- id
- BG001
- title
- Group 2 - Recurrent or Refractory Synovial Sarcoma
- description
- Group 3 - Recurrent or Refractory Rhabdomyosarcoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. cixutumumab: Given IV laboratory biomarker analysis: Correlative studies
- id
- BG002
- title
- Group 3 - Recurrent or Refractory Rhabdomyosarcoma
- description
- Group 4 - Recurrent or Refractory Adrenocortical Carcinoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. cixutumumab: Given IV laboratory biomarker analysis: Correlative studies
- id
- BG003
- title
- Grp 4-Recurrent or Refractory Adrenocortical Carcinoma
- description
- Group 5 - Recurrent or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. cixutumumab: Given IV laboratory biomarker analysis: Correlative studies
- id
- BG004
- title
- Grp 5-Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- description
- Group 6 - Recurrent or Refractory Neuroblastoma -MIBG Positive Without Measurable Disease. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. cixutumumab: Given IV laboratory biomarker analysis: Correlative studies
- id
- BG005
- title
- Grp 6 - Neuroblastoma-MIBG Positive Without Measurable Disease
- description
- Group 7 - Recurrent or Refractory Neuroblastoma -With Measurable Disease. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. cixutumumab: Given IV laboratory biomarker analysis: Correlative studies
- id
- BG006
- title
- Grp 7-Neuroblastoma With Measurable Disease
- description
- Group 8 - Recurrent Osteosarcoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. cixutumumab: Given IV laboratory biomarker analysis: Correlative studies
- id
- BG007
- title
- Group 8 - Recurrent Osteosarcoma
- description
- Group 9 - Recurrent or Refractory Wilms Tumor. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. cixutumumab: Given IV laboratory biomarker analysis: Correlative studies
- id
- BG008
- title
- Group 9 - Recurrent or Refractory Wilms Tumor
- description
- Group 10 - Recurrent or Refractory Retinoblastoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. cixutumumab: Given IV laboratory biomarker analysis: Correlative studies
- id
- BG009
- title
- Group 10 - Recurrent or Refractory Retinoblastoma
- description
- Total of all reporting groups
- id
- BG010
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 16
- group Id
- BG003
- value
- 8
- group Id
- BG004
- value
- 9
- group Id
- BG005
- value
- 18
- group Id
- BG006
- value
- 7
- group Id
- BG007
- value
- 8
- group Id
- BG008
- value
- 9
- group Id
- BG010
- value
- 93
- title
- <=18 years
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 5
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 0
- group Id
- BG010
- value
- 23
- title
- Between 18 and 65 years
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG010
- value
- 0
- title
- >=65 years
- param Type
- NUMBER
- title
- Age, Categorical
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 2
- upper Limit
- 7
- value
- 3
- group Id
- BG001
- lower Limit
- 12
- upper Limit
- 26
- value
- 17.5
- group Id
- BG002
- lower Limit
- 3
- upper Limit
- 22
- value
- 14
- group Id
- BG003
- lower Limit
- 10
- upper Limit
- 29
- value
- 14
- group Id
- BG004
- lower Limit
- 8
- upper Limit
- 28
- value
- 17
- group Id
- BG005
- lower Limit
- 2
- upper Limit
- 30
- value
- 10.5
- group Id
- BG006
- lower Limit
- 4
- upper Limit
- 26
- value
- 14.5
- group Id
- BG007
- lower Limit
- 3
- upper Limit
- 24
- value
- 14.5
- group Id
- BG008
- lower Limit
- 4
- upper Limit
- 14
- value
- 7
- group Id
- BG010
- lower Limit
- 2
- upper Limit
- 30
- value
- 13
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 6
- group Id
- BG004
- value
- 6
- group Id
- BG005
- value
- 8
- group Id
- BG006
- value
- 9
- group Id
- BG007
- value
- 3
- group Id
- BG008
- value
- 8
- group Id
- BG010
- value
- 55
- title
- Female
- categories
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 15
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 8
- group Id
- BG005
- value
- 12
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 7
- group Id
- BG008
- value
- 1
- group Id
- BG010
- value
- 61
- title
- Male
- param Type
- NUMBER
- title
- Gender
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 1
- group Id
- BG008
- value
- 1
- group Id
- BG010
- value
- 15
- title
- Hispanic or Latino
- categories
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 17
- group Id
- BG003
- value
- 8
- group Id
- BG004
- value
- 14
- group Id
- BG005
- value
- 18
- group Id
- BG006
- value
- 8
- group Id
- BG007
- value
- 9
- group Id
- BG008
- value
- 7
- group Id
- BG010
- value
- 96
- title
- Not Hispanic or Latino
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 1
- group Id
- BG010
- value
- 5
- title
- Unknown or Not Reported
- param Type
- NUMBER
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG010
- value
- 0
- title
- American Indian or Alaska Native
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG010
- value
- 5
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG010
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 3
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 3
- group Id
- BG008
- value
- 2
- group Id
- BG010
- value
- 15
- title
- Black or African American
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 13
- group Id
- BG003
- value
- 8
- group Id
- BG004
- value
- 12
- group Id
- BG005
- value
- 16
- group Id
- BG006
- value
- 6
- group Id
- BG007
- value
- 6
- group Id
- BG008
- value
- 6
- group Id
- BG010
- value
- 80
- title
- White
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG010
- value
- 0
- title
- More than one race
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 1
- group Id
- BG008
- value
- 1
- group Id
- BG010
- value
- 16
- title
- Unknown or Not Reported
- param Type
- NUMBER
- title
- Race (NIH/OMB)
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 18
- group Id
- BG003
- value
- 9
- group Id
- BG004
- value
- 14
- group Id
- BG005
- value
- 19
- group Id
- BG006
- value
- 9
- group Id
- BG007
- value
- 10
- group Id
- BG008
- value
- 8
- group Id
- BG010
- value
- 108
- title
- United States
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG010
- value
- 2
- title
- Canada
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 1
- group Id
- BG010
- value
- 6
- title
- Australia
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
- population Description
- Group 10, Recurrent or Refractory Retinoblastoma no patients were enrolled.
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle